Why Shares of Sarepta Therapeutics Skyrocketed Today
Shares of the clinical-stage biotech Sarepta Therapeutics bolted higher by over 50% today. Here's why.
Why I'm Buying Sarepta Therapeutics Stock
Sarepta Therapeutics got some great news from the FDA yesterday that sent shares soaring. Here's why the stock is definitely worth a deeper dive by risk-tolerant investors.
Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity
Sarepta Therapeutics is nearing the moment of truth for its Duchenne muscular dystrophy treatment eteplirsen. If all goes according to plan, this single drug could transform this tiny biotech into one of the best performing healthcare stocks in 2015. Here's why.